The company dosed three patients in two different hospitals in Israel under a compassionate use program for the treatment of COVID-19.
MARCH 30, 2020
Pluristem Therapeutics, a Haifa-based regenerative-medicine company, has treated its first three coronavirus patients in Israel with its placenta-based cell-therapy product.
“In this time of emergency, we are honored to be taking part in the global effort to support patients and healthcare systems,” Pluristem president and CEO Yaky Yanay said.
The company dosed three patients in two different hospitals in Israel under a compassionate-use program for the treatment of COVID-19. It was approved by the Health Ministry.
Pluristem expects to enroll additional Israeli patients in the coming days. The company will share updates on clinical outcomes once significant data has been gathered, it said in a press release.
All the patients who have received the therapy are high risk. They are older, have preexisting medical conditions and have been intubated with a ventilator.
“Pluristem is closely following the medical condition of these patients in conjunction with the hospitals’ medical professionals delivering the care,” the press release said.
Pluristem said its PLX cells are “allogeneic mesenchymal-like cells that have immunomodulatory properties,” meaning they induce the immune system’s natural regulatory T cells and M2 macrophages. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).
Previous preclinical findings regarding PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury.
The company is in discussions with regulators in the United States and Europe to “define our clinical strategy for COVID-19,” Yanay said.
“Pluristems’s advanced manufacturing capabilities enable us to serve potential needs of treating large numbers of patients under compassionate use and clinical studies across numerous countries and hospitals in accordance with our expansion program and regulatory approvals,” he said. “We are facing a very different global condition right now, and the entire Pluristem team is committed to be an important part of the solution.”
